



3 Shifts Reshaping Alzheimer’s Trial Execution

Pipeline, enrollment, and design considerations defining next-generation AD trials

1: The Landscape Shift



~70%

of investigational AD drugs are disease-modifying therapies

2025 AD pipeline¹



182 clinical trials



53% small molecules



47% biologics

Early-stage intervention is now the main focus of development.

2: The Enrollment Bottleneck

Preclinical patients and early-stage participants may not yet recognize the need for care.



Find

community + primary care + memory clinics



Screen

blood-based biomarkers



Refer

central review



Support

site tools + outreach

3: The Trial Design Response



Adaptive Design

Adjust cohorts based on emerging data



Biomarker Strategy

Reduce burden while preserving rigor



Blinding Protection

Use rater and safety controls to limit bias



Why it matters

Approved anti-amyloid therapies, biomarker-driven diagnosis, and the shift toward preclinical patients are reshaping AD trial operations.

Sponsor readiness starts here



Build recruitment pathways for preclinical and early-stage patients



Match design to mechanism and treatment history



Protect data integrity from screening through assessment



Visit us at premier-research.com or contact us at info@premier-research.com

Explore 5 strategic imperatives for smarter AD trial execution

